Detailed Insights on Glucokinase – H2 2020 Pipeline Review – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Glucokinase – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Glucokinase – Pipeline Review, H2 2020, outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders and Infectious Disease which include indications Type 2 Diabetes, Type 1 Diabetes (Juvenile Diabetes), Coronavirus Disease 2019 (COVID-19), Diabetes and Obesity.
Furthermore, this report also reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Topics Covered:
1. Introduction
2. Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Overview
3. Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
4, Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
5. Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Companies Involved in Therapeutics Development
- AstraZeneca Plc
- Eli Lilly and Co
- Hua Medicine Shanghai Ltd
- Impetis Biosciences Ltd
- Kriya Therapeutics Inc
- Ligand Pharmaceuticals Inc
- Merck & Co Inc
- Pfizer Inc
- Sanwa Kagaku Kenkyusho Co Ltd
- vTv Therapeutics Inc
6. Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Drug Profiles
7. Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Discontinued Products
8. Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Product Development Milestones
9. Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact
- Disclaimer
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/uk6w10
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
